Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Oktober 2024

Genmab — Oktober 2024

Planlagt Fastgjort Låst Flyttet Genmab
991 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #820

    on HALO ; my understanding is that EPO will send a written form of the decision in a few weeks, JNJ then has ~2 months to appeal. During the appeal the EPO decision is suspended and the patent remains in force. Such an appeal can take ~2 years

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #821

      Maybe we can learn more if we see that EPO write up, I assume that will be public info

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #822

        Third week in a row that the US volume was higher than the Copenhagen volume. I am not sure if we have seen that before

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #823

          In my opinion it was US that took Genmab down. Would not be surpriced to se them take it up again. Well JNJ has take the uncertainty about their faspro in consideration when they decide the opt. on Erzo. Thanks EL for the link to Traverse Biotech - interesting target for Genmab.

          1 Reply Last reply
          0
          • B Offline
            B Offline
            bikube
            wrote on sidst redigeret af
            #824

            Kursen i U S plejer at være lidt højere end i DK både på GMAB og Novo.

            1 Reply Last reply
            0
            • L Offline
              L Offline
              lahn1
              wrote on sidst redigeret af
              #825

              Dollar er sgu da også højre end danske kroner !. Niveauet er ved at blive lidt for lavt herinde. God weekend 😉

              1 Reply Last reply
              0
              • B Offline
                B Offline
                bikube
                wrote on sidst redigeret af
                #826

                Lahn - tror du kke, at jeg omregner $ til DKK inden jeg skriver ? Hvis du vil give lidt ekstra, kan du jo købe GMAB i U S.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #827

                  Bispecific Antibodies, Novel Combinations Highlight Continued Treatment Evolution in Follicular Lymphoma https://www.onclive.com/view/bispecific-antibodies-novel-combinations-highlight-continued-treatment-evolution-in-follicular-lymphoma

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    lahn1
                    wrote on sidst redigeret af
                    #828

                    Undskyld bikube, den var sagt for sjov. Fortsat god weekend.

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bikube
                      wrote on sidst redigeret af
                      #829

                      I orden Lahn.

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #830

                        Godmorgen 🙂

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          ProinvestorNEWS
                          wrote on sidst redigeret af
                          #831

                          Genmab-investorerne får tirsdag morgen nyt fra Schweiz, hvor Novartis’ regnskab også byder på tal for der også byder på sklerosemidlet Kesimpta, der er udviklet af det danske biotekselskab. Genmab modtager royalties på 10 pct. af salget, der i andet kvartal blev på 799 mio. dollar.

                          1 Reply Last reply
                          0
                          • B Offline
                            B Offline
                            bikube
                            wrote on sidst redigeret af
                            #832

                            Er der nogen, der har set tallene fra Novartis ?

                            1 Reply Last reply
                            0
                            • B Offline
                              B Offline
                              bikube
                              wrote on sidst redigeret af
                              #833

                              Undskyld - det er i morgen, de kommer.

                              1 Reply Last reply
                              0
                              • exitnuE Offline
                                exitnuE Offline
                                exitnu
                                wrote on sidst redigeret af
                                #834

                                Upcoming event: Oct 29, 2024 - Third quarter 2024 results

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  gdn55
                                  wrote on sidst redigeret af
                                  #835

                                  Hu hej hvor det går, med kursen. Forstod ikke hvordan den fik lov til at stige 0,95% i fredags, men pyt nu er vi næsten tilbage, som i torsdag, og imorgen er der atter en dag. Mit store spørgsmål hvor langt ned skal den inden buddet kommer.

                                  1 Reply Last reply
                                  0
                                  • J Offline
                                    J Offline
                                    JKY_VH
                                    wrote on sidst redigeret af
                                    #836

                                    Det ved vist kun JNJ

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #837

                                      Godmorgen 🙂

                                      1 Reply Last reply
                                      0
                                      • L Offline
                                        L Offline
                                        LP90
                                        wrote on sidst redigeret af
                                        #838

                                        Godmorgen 🙂

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Stroka
                                          wrote on sidst redigeret af
                                          #839

                                          God morgen 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper